Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:KERX
  • CUSIP: 49251510
  • Web: www.keryx.com
Capitalization:
  • Market Cap: $700.69 million
  • Outstanding Shares: 108,466,000
Average Prices:
  • 50 Day Moving Avg: $6.13
  • 200 Day Moving Avg: $5.76
  • 52 Week Range: $4.03 - $7.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.09
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: $36.98 million
  • Price / Sales: 18.95
  • Book Value: ($0.21) per share
  • Price / Book: -30.76
Profitability:
  • EBIDTA: ($121,500,000.00)
  • Net Margins: -584.76%
  • Return on Equity: -270.26%
  • Return on Assets: -67.88%
Debt:
  • Debt-to-Equity Ratio: 5.69%
  • Current Ratio: 8.75%
  • Quick Ratio: 7.42%
Misc:
  • Average Volume: 1.40 million shs.
  • Beta: 4.93
  • Short Ratio: 15.92
 

Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals (NASDAQ:KERX) posted its earnings results on Thursday, May, 4th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.03. The business earned $11.82 million during the quarter, compared to analysts' expectations of $10.19 million. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. Keryx Biopharmaceuticals's revenue for the quarter was up 73.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.39) EPS. View Keryx Biopharmaceuticals' Earnings History.

Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 12 month price targets for Keryx Biopharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Keryx Biopharmaceuticals' share price to reach $8.60 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.

What are analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

  • 1. Maxim Group analysts commented, "After recently announcing that the nation’s largest Medicare Part D plan sponsor has added Auryxia to its Medicare Part D plan formularies, the company today announced that they have secured formulary status at another large Medicare Part D sponsor and that now 95% of dialysis patients on phosphate binders across Medicare Part D and commercial insurance providers now have unrestricted access to Auryxia." (5/1/2017)
  • 2. According to Zacks Investment Research, "Keryx’s top line is driven by sales of its lead product, Auryxia. We are encouraged by the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication. Moreover, the IDA market holds great potential. However, the company took a hit due to an imminent interruption in the supply of Auryxia in August, because of issues related to the conversion of the active pharmaceutical ingredient (API) into the finished product by its contract manufacturer. Consequently, the company withdrew its guidance for 2016. The supply issue is not expected to be resolved any time soon and will lead to a significant decline in sales. Moreover, it will continue to hurt on Keryx’s shares until supply normalizes. Given that the company is heavily dependent on Auryxia for growth, this development is concerning. Loss estimate have been rising ahead of the company’s Q3 earnings release." (11/1/2016)
  • 3. JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)
  • 4. FBR & Co analysts commented, "We are previewing Keryx’s 2Q16 financial results, following an update with management and analysis of IMS script data for Keryx’s approved drug, Auryxia (ferric citrate). KERX shares are up approximately 85% since our upgrade on February 29, 2016, versus a gain of ~12% for the S&P 500 Index, which reflects our thesis and KERX’s continued execution. In 2Q16, IMS scripts grew ~37% to 7,164 scripts, compared with 1Q16 script growth of ~16% to 5,217 scripts. Assuming a capture rate of 57%, we think total script growth could reach 12,565 for the quarter. We had an opportunity to speak with management and discuss the company’s corporate progress and provide the following takeaways: (1) we believe the 2Q16 IMS script growth highlights continued execution with the Auryxia launch; (2) we see a potential tailwind for Auryxia sales from a price increase in 2H16; and (3) long term, we believe the expansion of Auryxia’s use in non-dialysis Iron Deficiency Anemia (IDA) patients has significant potential to increase prescribing physician awareness and expand the market opportunity for the drug." (7/25/2016)

Are investors shorting Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totalling 17,498,249 shares, a drop of 20.3% from the April 28th total of 21,948,085 shares. Based on an average daily volume of 2,126,582 shares, the short-interest ratio is currently 8.2 days. Currently, 16.4% of the shares of the stock are short sold.

Who are some of Keryx Biopharmaceuticals' key competitors?

Who owns Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Baupost Group LLC MA (23.78%), Vanguard Group Inc. (6.36%), Abrams Capital Management L.P. (5.31%), State Street Corp (3.21%), FMR LLC (2.15%) and Ameriprise Financial Inc. (1.52%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, James F Oliviero III, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Who sold Keryx Biopharmaceuticals stock? Who is selling Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Ameriprise Financial Inc., FMR LLC, First Trust Advisors LP, Morgan Stanley, Oppenheimer & Co. Inc., TIAA CREF Investment Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have sold Keryx Biopharmaceuticals stock in the last year include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Who bought Keryx Biopharmaceuticals stock? Who is buying Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Old West Investment Management LLC, State Street Corp, Vanguard Group Inc., Endurant Capital Management LP, Point72 Asset Management L.P., Credit Suisse AG, Parametric Portfolio Associates LLC and Bank of Montreal Can. View Insider Buying and Selling for Keryx Biopharmaceuticals.

How do I buy Keryx Biopharmaceuticals stock?

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Keryx Biopharmaceuticals stock cost?

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $6.46.

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $8.60 (33.13% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Maxim GroupBoost Price TargetBuy$7.00 -> $9.00N/AView Rating Details
1/11/2017Citigroup IncUpgradeSell -> Neutral$7.00N/AView Rating Details
11/19/2016FBR & CoReiterated RatingHoldN/AView Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformN/AView Rating Details
8/3/2016Cowen and CompanyReiterated RatingNeutralN/AView Rating Details
8/2/2016Raymond James Financial, Inc.Boost Price TargetOutperform$7.00 -> $10.00N/AView Rating Details
8/2/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$9.00 -> $10.00N/AView Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50N/AView Rating Details
2/26/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralN/AView Rating Details
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00N/AView Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$25.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.18)($0.21)$10.19 million$11.82 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.25)($0.32)$9.65 million$9.53 millionViewListenView Earnings Details
11/9/2016Q316($0.22)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015Q3 2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.70 million$0.57 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.39 million$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.23)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.10)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-0.69 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS

Dividends

Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Ownership Percentage: 3.08%
Institutional Ownership Percentage: 61.74%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/28/2017Scott A. HolmesCFOSell1,219$5.89$7,179.91View SEC Filing  
4/24/2017John F. NeylanInsiderSell1,209$5.73$6,927.57View SEC Filing  
4/17/2017Brian AdamsGeneral CounselSell1,090$5.75$6,267.50View SEC Filing  
4/5/2017Brian AdamsGeneral CounselSell642$5.80$3,723.60View SEC Filing  
4/5/2017Greg MadisonInsiderSell911$5.80$5,283.80View SEC Filing  
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Keryx Biopharmaceuticals (NASDAQ:KERX)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in Keryx Biopharmaceuticals (KERX) Declines By 20.3%
www.americanbankingnews.com - May 27 at 7:06 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 22 at 6:20 PM
finance.yahoo.com logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 5:35 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $14.08 Million
www.americanbankingnews.com - May 12 at 1:18 PM
finance.yahoo.com logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 6:38 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 10 at 8:24 PM
finance.yahoo.com logoKeryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 12:06 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 9 at 12:16 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 11:53 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 8 at 10:26 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 8 at 11:43 AM
streetinsider.com logoKeryx Biopharma (KERX): Expanding Model And Raising PT - Maxim - StreetInsider.com
www.streetinsider.com - May 8 at 9:21 AM
finance.yahoo.com logoKeryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
finance.yahoo.com - May 5 at 6:07 PM
finance.yahoo.com logoEdited Transcript of KERX earnings conference call or presentation 4-May-17 12:00pm GMT
finance.yahoo.com - May 5 at 6:07 PM
seekingalpha.com logoKeryx Biopharma Q1 revenues up 74%
seekingalpha.com - May 4 at 11:18 PM
finance.yahoo.com logoKeryx Biopharmaceuticals Announces First Quarter 2017 Financial Results - Yahoo Finance
finance.yahoo.com - May 4 at 6:18 PM
streetinsider.com logoKeryx Biopharma (KERX) Misses Q1 EPS by 1c, Beat on Revenues - StreetInsider.com
www.streetinsider.com - May 4 at 6:18 PM
seekingalpha.com logoKeryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 4 at 6:18 PM
finance.yahoo.com logoKeryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 6:18 PM
finance.yahoo.com logoInvestor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 6:18 PM
finance.yahoo.com logoKeryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat
finance.yahoo.com - May 4 at 6:18 PM
finance.yahoo.com logoKeryx Biopharma reports 1Q loss
finance.yahoo.com - May 4 at 6:17 PM
americanbankingnews.com logoPositive Media Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Share Price
www.americanbankingnews.com - May 4 at 12:48 PM
streetinsider.com logoKeryx Biopharma (KERX) Says Auryxi is Now on Formulary at All Major Medicare Part D Plans - StreetInsider.com
www.streetinsider.com - May 3 at 8:39 PM
seekingalpha.com logoUroGen Pharma Readies $45 Million IPO
seekingalpha.com - May 2 at 10:54 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 1 at 11:24 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Stock Price
www.americanbankingnews.com - May 1 at 7:32 PM
finance.yahoo.com logoKeryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans
finance.yahoo.com - May 1 at 1:05 PM
finance.yahoo.com logoWhat to Expect from Keryx (KERX) Stock This Earnings Season?
finance.yahoo.com - April 28 at 7:04 PM
americanbankingnews.com logoSomewhat Negative News Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Stock Price
www.americanbankingnews.com - April 28 at 12:38 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 27 at 12:18 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 25 at 5:44 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Earns News Impact Score of -0.08
www.americanbankingnews.com - April 25 at 1:32 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Getting Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 22 at 9:35 AM
globenewswire.com logoKeryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017 - GlobeNewswire (press release)
globenewswire.com - April 20 at 11:11 AM
americanbankingnews.com logo Analysts Expect Keryx Biopharmaceuticals (KERX) to Post -$0.18 EPS
www.americanbankingnews.com - April 19 at 10:28 PM
americanbankingnews.com logoVery Positive Press Coverage Likely to Affect Keryx Biopharmaceuticals (KERX) Stock Price
www.americanbankingnews.com - April 19 at 10:31 AM
finance.yahoo.com logoKeryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017
finance.yahoo.com - April 18 at 10:48 AM
americanbankingnews.com logoVery Favorable News Coverage Very Likely to Effect Keryx Biopharmaceuticals (KERX) Share Price
www.americanbankingnews.com - April 16 at 8:14 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 13 at 9:30 AM
finance.yahoo.com logoLawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders ... - Yahoo Finance
finance.yahoo.com - April 11 at 5:54 PM
finance.yahoo.com logoLawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation
finance.yahoo.com - April 10 at 10:50 AM
fool.com logoHere's Why Keryx Biopharmaceuticals Jumped 27.3% in March - Motley Fool
www.fool.com - April 7 at 6:00 PM
finance.yahoo.com logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 6:00 PM
finance.yahoo.com logoWhy Is Keryx (KERX) Up 27.4% Since the Last Earnings Report?
finance.yahoo.com - April 7 at 10:40 AM
finance.yahoo.com logoHere's Why Keryx Biopharmaceuticals Jumped 27.3% in March
finance.yahoo.com - April 7 at 10:40 AM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 31 at 2:07 PM
finance.yahoo.com logoKeryx's Auryxia Added to Largest Medicare Part D Plan
finance.yahoo.com - March 22 at 6:19 PM
americanbankingnews.com logoKeryx Biopharmaceuticals (KERX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - March 20 at 4:22 PM
finance.yahoo.com logoKeryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies
finance.yahoo.com - March 20 at 10:45 AM

Social

Chart

Keryx Biopharmaceuticals (KERX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff